Potentiation of apomorphine and d-amphetamine effects by naloxone
Abstract
The effects of naloxone, an opiate antagonist, on the stereotypic behavior and locomotor activity induced by apomorphine and d-amphetamine were studied. Groups of adult male Sprague-Dawley rats were first tested for stereotypy and locomotor activity after apomorphine (0.0 – 2.0 mg/kg) or d-amphetamine (0.0 – 10.0 mg/kg). Groups were subsequently tested with saline or naloxone (1.0 – 4.0 mg/kg) plus the previously used dosage of apomorphine or d-amphetamine. Naloxone alone did not produce stereotypy, but did significantly reduce locomotor activity. Naloxone potentiated apomorphine and d-amphetamine induced stereotypy. Apomorphine-induced activity was increased by naloxone, but d-amphetamine-induced activity at 2.5 mg/kg was reduced. The results are compatible with the suggestion that naloxone may potentiate both apomorphine and d-amphetamine by inhibiting an opiate receptor mechanism which normally interacts with catecholamine neuronal action.
References (13)
- S. Amir et al.
Neuropharm.
(1979) - A. Arnsten et al.
Life Sci.
(1979) - P. Dettmar et al.
Neuropharm.
(1978) - P. Kelly et al.
Brain Res.
(1975) - H. Lal
Life Sci.
(1975) - B. Costall et al.
Psychopharm.
(1975)
Cited by (34)
The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat
2009, Behavioural Brain ResearchAmphetamine produces its rewarding effects by enhancing dopamine transmission in the mesocorticolimbic pathway. Several studies have also suggested the involvement of the endogenous opioid system in mediating the neurochemical and behavioural effects of amphetamine. The aim of this study was to investigate the effect of the unselective opioid receptor antagonist naltrexone (NTX) on reinstatement of amphetamine self-administration in the rat. Animals were trained to self-administer amphetamine under a fixed ratio 1 (FR1) schedule (0.1 mg/kg/infusion). After receiving a stable drug intake the amphetamine was replaced with saline and the animals went through an extinction period. After reaching the extinction criteria, animals were pre-treated with NTX (0, 0.3, 1.0 and 3.0 mg/kg, s.c.) 30 min before giving a priming dose of amphetamine (0.5 mg/kg s.c). To study the effects of NTX on operant behaviour, animals were trained to lever press for food pellets under a FR1 schedule of reinforcement. Results from the present study shows that a single injection of amphetamine reinstated self-administration behaviour. NTX (0.3 and 1.0 mg/kg) significantly attenuated the amphetamine-induced reinstatement but NTX had no effect at any dose studied on food taking behaviour. These results show that NTX attenuates reinstatement of amphetamine self-administration in rats without suppressing general behaviour, implicating a functional role for opioid receptors in modulating amphetamine seeking behaviour.
3 -Methyl-5-hydroxy-5-trichloromethyl-1 H-1 -pyrazolcarboxyamide induces antinociception
2001, Pharmacology Biochemistry and BehaviorThe antinociceptive action of a novel pyrazole-derived compound, 3-methyl-5-hydroxy-5-trichloromethyl-1H-1-pyrazolcarboxyamide (MPCA) was evaluated using the formalin and tail-immersion tests in mice. Anti-inflammatory activity was assessed by paw plethysmometry in adult rats using the carrageenin-induced paw edema test. Subcutaneous administration of MPCA (22, 66, and 200 mg/kg) induced a dose-dependent decrease in the time spent licking during the neurogenic and inflammatory phases of the formalin test, and preadministration of naloxone (1 mg/kg, sc) did not prevent MPCA-induced (200 mg/kg, sc) antinociception. Naloxone decreased the spontaneous locomotor activity of mice, while MPCA had no effect on locomotion. In contrast, administration of the opioid antagonist caused a significant increase in the locomotor behavior of mice previously injected with MPCA. MPCA was devoid of antinociceptive action by the tail-immersion test and of anti-inflammatory activity. Moreover, MPCA had no effect on the motor performance of mice in the rotarod test. These results suggest that MPCA induces antinociception in the neurogenic and inflammatory phases of the formalin test, an effect that does not involve opioid receptors.
Blockade by naloxone of cocaine-induced hyperactivity, reverse tolerance and conditioned place preference in mice
1997, Behavioural Brain ResearchCocaine-induced hyperactivity was inhibited by a single administration of naloxone (2 and 5 mg/kg, i.p.), an opioid receptor antagonist, and naloxone administered prior to and during the chronic injection of cocaine attenuated the development of both cocaine-induced reverse tolerance and conditioned place preference (CPP). Dopamine (DA) receptor supersensitivity which developed in cocaine-induced reverse tolerant or CPP mice, was also inhibited by naloxone. Furthermore, naloxone reduced an apomorphine-induced striatal dopaminergic action, climbing behavior. Therefore, the present studies suggest that cocaine-induced dopaminergic behaviors, such as hyperactivity, reverse tolerance and CPP, may be commonly produced via activation of an opioid receptor. The development of DA receptor supersensitivity may be a possible common mechanism of cocaine-induced reverse tolerance and CPP, since cocaine-induced changes in sensitivity to apomorphine, as well as apomorphine-induced climbing behavior in mice, were both inhibited by naloxone.
THe effect of naloxone on spontaneous and evoked dopamine release in the central and peripheral nervous systems
1996, Life SciencesA number of studies have reported that the opiate antagonist naloxone (NX) inhibits behaviors dependent upon central dopamine (DA) release. However, equally compelling evidence from other studies suggests that NX excites a facilitatory effect. The present review was undertaken to resolve the issue by critically evaluating the effects of NX on DA release; the substrate subserving these behaviors. Included are studies reporting an effect of NX on spontaneous as well as drug altered DA release in various central regions. In the preponderant majority of these studies, NX was found to significantly enhance DA release in the virtually every major DA pathway, irrespective of whether DA release was initially stimulated or inhibited by various agents. It is concluded that NX most probably enhances behaviors induced by DA release, especially when administered in low, specific doses. Studies finding an inhibitory effect of NX on such behaviors may inadvertently produce conditions which mask the stimulatory effects of NX on DA release-dependent behaviors.
Reductions in locomotor activity following central opioid receptor subtype antagonists in rats
1996, Physiology and BehaviorOpioid agonists produce biphasic (decreases then increases) effects upon activity in rats. General opioid antagonists typically suppress activity. Selective opioid antagonists reduce weight and food intake. However, the latter effects cannot fully account for the former effects. To assess the possibility that selective opioid antagonists might decrease weight by increasing activity, the present study examined whether central administration of either mu (β-funaltrexamine: 20 μg), mu1 (naloxonazine: 50 μg), delta1 ([d-Ala2,Leu5,Cys6]enkephalin: 40 μg), delta2 (naltrindole isothiocyanate: 20 μg), or kappa1 (nor-binaltorphamine: 20 μg) opioid antagonists altered total, ambulatory, or stereotypic activity. Each of the antagonists significantly reduced total (mu: 18%, mu1 : 31%, delta1: 42%, delta2: 37%, kappa1: 31%), ambulatory (mu: 17%, mu1 : 27%, delta1: 34%, delta2: 37%, kappa1 : 31%), and stereotypic (mu: 19%, mu1 : 34%, delta2: 49%, delta2: 37%, kappa1: 31%) activity on the first day. All three activity measures were reduced by delta1 and delta2 antagonism on the second day, whereas mu antagonism reduced total and stereotypic activity on the second day. The activity reductions induced by selective opioid receptor subtype antagonists parallel effects induced by general opioid antagonism, and suggest that antagonist-induced weight loss effects independent of intake reductions are not due to antagonist-induced hyperactivity.
Naloxone reduces social locomotor activity in rats
1992, Pharmacology, Biochemistry and BehaviorNaloxone, a nonspecific opioid antagonist, has been found to decrease the activity and social behavior of rats tested in pairs but the effects on individual locomotor activity have been equivocal. In the present study, groups of male Long-Evans hooded rats recieved naloxone (1 or 4 mg/kg, IP) or vehicle alone (isotonic saline) 30 min prior to testing sessions. Individual locomotor activity was measured in two activity boxes (41-cm3) equipped with two infrared photobeams using daily 30-min testing sessions for 5 consecutive days. Following a 1-week washout period (no testing), activity and social attraction (paired distance and contact) were examined in pairs of rats from each group using daily 15-min testing sessions for 4 consecutive days. Locomotor activity and its habituation were not significantly affected by naloxone in rats tested individually. However, both doses of naloxone significantly reduced paired locomotor activity compared to the control group. Measures of social attraction were not significantly affected by naloxone. The present findings suggest that naloxone does not produce nonspecific depressant effects on activity but rather may antagonize opioid release in situational contexts of high arousal (e.g., social activity) with consequent reduction of activity.